Big Pharma Performance Before, During and Beyond the Global Recession

A comparative analysis of leading pharmaceutical company sales dynamics over the period 2005-14

Between 2009 and 2014, the expiry burden will reach a tipping point, sending year-on-year Pharma sales growth rates negative in 2012 and 2013. In total, expiries are expected to cut 2009–14 prescription pharmaceutical sales growth from 4.3% to 0.3%. If Pharma is to avoid a continuation of the 2005–08 stock market revaluation of its worth, it must take action.

Three broad strategies are available:

• Repositioning into ‘high-growth’ segments of the sector and emerging markets
• Diversifying away from branded pharmaceuticals
• Cost cutting

Click here to view the four-page executive summary of Big Pharma Performance Before, During and Beyond the Global Recession report.

These strategies can be pursued through licensing, layoffs and restructuring, and M&A. Many Pharma’s have already begun to take such steps, most radically seen with the mega-mergers of Pfizer-Wyeth and Merck-Schering-Plough. Nevertheless, as the economy has moved into recovery in Q309, Pharma has already reverted to its 2005–08 trend of underperforming the wider stock market, a trend that is expected continue unless Pharma fails to find a way of overcoming the expiry threat or the recovery falters and the global economy falls into a double-dip recession.

This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global recession. It places the Pharma sector in the context of other major industry sectors and analyzes the internal dynamics behind pharmaceutical companies' performance.

Use this report to:

• Assess Pharma's sales and stock market performance in relation to other major industry sectors
• Evaluate the strategic shifts within the prescription pharmaceutical market and identify the high- and low-growth sectors of the industry
• Quantify the historical and forecast impact of generics on pharma's sales growth rate

Click here to view the four-page executive summary of this report.

Big Pharma Performance Before, During and Beyond the Global Recession will be delivered as a PDF via e-mail. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product. For more information, please call 877/437-4276 or e-mail account manager Maureen Croce at mcroce@hcpro.com.

• Reports

• Other Life Sciences Products